Compare Godaddy Inc (GDDY) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Eli Lilly And Co — how do they compare? Godaddy Inc trades at $104.43 (market cap $13.07B), while Eli Lilly And Co trades at $1,174.47 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 79.6× Godaddy Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and Eli Lilly And Co for 93 Days on average.
| GDDY | LLY | |
|---|---|---|
Market Cap | $13.07B | $1.04T |
Volume | 1,831,274 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $135.18 | $1.28K |
52-Week Low | $75.07 | $799.57 |
Typical Hold Time | 64 Days | 93 Days |
Enterprise Value | $15.75B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.7, up 7.7% in the last 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $4.95B in 2025 and net income of $875M, with consistent earnings beats in recent quarters. However, the stock faces headwinds from a securities class action lawsuit alleging misrepresentations about domain contract terms, with a lead plaintiff deadline of October 20, 2026.
The outlook is mixed: strong profitability and earnings momentum support upside, but legal risks and a consensus price target of $96.20 suggest caution. Investors should weigh robust fundamentals against potential litigation impacts and market sentiment shifts.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
